Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 2 Neoplasm Metastasis 1 Melanoma 1 Glioblastoma 1 Carcinoma 1

Interventions

Temozolomide 31 Radiotherapy 25 Magnetic Resonance Spectroscopy 17 Radiation 13 Surgical Procedures, Operative 12 Specimen Handling 9 Radiotherapy, Conformal 9 Bevacizumab 9 Immunoglobulin G 8 Disulfides 8 Carmustine 8 Vorinostat 7 Radiotherapy, Intensity-Modulated 7 Erlotinib Hydrochloride 7 Chemotherapy, Adjuvant 7 temsirolimus 6 cediranib 6 Sirolimus 6 motexafin gadolinium 5 Sorafenib 5 Nivolumab 5 Cilengitide 5 Carboplatin 5 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5 tipifarnib 4 Lapatinib 4 Congresses as Topic 4 veliparib 3 Procarbazine 3 O(6)-benzylguanine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Glioblastoma × Craniotomy × Clear all

NCT01413438 2017-07-02

Bevacizumab With or Without Surgery for Adult Glioblastomas

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡